NR indicates not reported; RR, relapse rate; MVA, multivariable analysis; HR, hazard ratio; PFS, progression-free survival; CIR, cumulative incidence of relapse; and RI, relapse incidence.

^aNumber of patients with mutated KIT/total patients studied.

^bAge range and median are provided for all patients in the study including 113 patients with t(8;21) and 90 patients with inv(16).

^cMedian follow-up is provided for all patients in the study including 82 patients with t(8;21) and 39 with inv(16).

^dMedian follow-up is provided for all patients in the study including 82 patients with t(8;21) and 94 with inv(16).

^eOutcome analyses were performed on a subset of 60 patients in whom KIT mutation status was assessed.

^fAge range and median are provided for all patients in the study including 56 patients with t(8;21) and 47 with inv(16).

^g Median follow-up is provided for all patients in the study including 56 patients with t(8;21) and 47 with inv(16).

^hThe KIT gene comprises 21 exons.

ⁱMedian follow-up for OS.

^jOutcome analyses based on 36 patients who received intensive chemotherapy; all 36 patients were below the age of 60 years and 19 of 36 (53%) patients carried a KIT mutation.

^kOutcome analyses were performed on subset of 57 patients in whom KIT mutation status was assessed.

^lMean age is provided instead of median age.

^mOutcome analyses based on 42 patients who received intensive chemotherapy; all 42 patients were below the age of 60 years and 13 of 42 (31%) patients carried a KIT mutation.

ⁿAnalysis based on 5 patients with KIT exon 8 mutations.